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Background: CYP17A1 gene encodes P450c17 proteins, which is a key enzyme that catalyzes the formation of sex
hormones. Many clinical studies showed that sex hormones levels play an important role in the pathogenesis of
coronary artery disease (CAD). However, the relationship between CYP17A1 genetic polymorphisms and CAD
remains unclear. The aim of this study was to investigate the association of CYP17A1 genetic polymorphisms with
CAD in a Han population of China.
Methods: A total of 997 people include 490 patients and 507 controls were selected for the present study. Five
single-nucleotide polymorphisms (SNPs) (rs4919686, rs1004467, rs4919687, rs10786712, and rs2486758) were
genotyped by using the real-time PCR (TaqMan) method.
Results: For men, the rs10786712 was found to be associated with CAD in a recessive model (P = 0.016), after
adjustment of the major confounding factors, the significant difference was retained (OR = 1.644, 95% confidence
interval [CI]: 1.087-2.488, P = 0.019). For women, the rs1004467 was also found to be associated with CAD in a dominant
model (P = 0.038), the difference remained statistically significant after multivariate adjustment (OR = 1.623, 95%
CI: 1.023-2.576, P = 0.040). The distribution of rs4919687 genotypes showed a significant difference between CAD
and control participants in a recessive model (P = 0.019), the significant difference was retained after adjustment
for covariates (OR = 0.417, 95% CI: 0.188-0.926, P = 0.032).
Conclusion: Rs1004467, rs4919687, rs10786712 of CYP17A1 gene are associated with CAD in Han population of
China. The TT genotype of rs10786712 could be a protective genetic marker of CAD in men. The CC genotype of
rs1004467 and the AA genotype of rs4919687 could be risk genetic markers of CAD in women. However, large
sample size study including other SNPs of CYP17A1 should be performed in future studies.
Keywords: CYP17A1, Single nucleotide polymorphism, Coronary artery disease, Case control studyIntroduction
Coronary artery disease (CAD) is a complex multifactorial
disorder resulting from several susceptibility genes and
multiple environmental determinants [1,2]. Recently, gen-
etic basis of CAD has gained considerable interest [3], her-
itable factors accounted for 40%-60% in occurrence and
development of CAD [4]. Various genes have been shown
to be associated with CAD [5,6]. Some large-scale associ-
ation studies have identified many common, uncommon* Correspondence: xiangxie999@sina.com; myt_xj@sina.com
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located on chromosome 10q24.3, is mainly expressed in the
adrenal glands and gonads. This gene encodes a member of
enzymes of the cytochrome P450 superfamily. The cyto-
chrome P450 proteins are monooxygenases and responsible
for not only the metabolism of xenobiotics but also a host
of endogenous substance whose metabolites have critical
roles in the maintenance of cardiovascular health [9,10].
Mounting evidences have demonstrated that CYP enzymes
are involved in the pathogenesis of CAD. For example, the
CYP8A1 predominantly in vascular endothelial and smooth
muscle cells, and acts mainly as an enzyme that convertss is an Open Access article distributed under the terms of the Creative
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some studies suggested that gene polymorphisms of
CYP8A1 were associated with cardiovascular risk [11]. In
addition, CYP1A1, CYP1A2 (metabolize tobacco polycyclic
aromatic hydrocarbons and aromatic amines during smok-
ing) [12,13], CYP2C8, CYP2J2 ([EET] synthesis) [14,15],
CYP11B2 (aldosterone synthesis) [16], CYP17, and CYP19
(synthesis of sex hormones) [17], have been demonstrated
to be associated with CAD.
In humans, CYP17A1 gene is responsible for the synthe-
sis of P450c17 proteins, which is a key enzyme in the ste-
roidogenic pathway. CYP17A1 genetic mutations affect
the synthesis of steroids, which are the precursors of sex
hormones. Some evidences have indicated that the levels
of sex hormones can affect the development of cardiovas-
cular and cerebrovascular diseases [18].
Recently, two large-scale association analyses identified
13 new susceptibility loci for CAD including CYP17A1
gene [19,20]. Adam S Butterworth et al. [21] selected 15596
patients with CAD and 34992 controls to examine 2100
genes including 49094 genetic variations, and suggested
that CYP17A1 gene is one of the susceptibility genes for
CAD. However, the relation between CYP17A1 gene and
CAD in Chinese population remains unclear. Therefore, in
the present study, we aimed to assess the association
between the polymorphisms of CYP17A1 and CAD in
Chinese Han population.
Methods
Ethical approval of the study protocol
This study was conducted according to the standards of
the Declaration of Helsinki, and was approved by the
Ethics Committee of the First Affiliated Hospital of Xinjiang
Medical University (Xinjiang, China). Written informed
consent was obtained from each participant, and explicitly
provided permission for DNA analyses as well as collec-
tion of relevant clinical data.
Subjects
Study population was from a Han population who lived in
the Xinjiang Uygur Autonomous Region of China, all sub-
jects attended as inpatients and had a differential diagnosis
for chest pain encountered in the Cardiac Catheterization
Laboratory of First Affiliated Hospital of Xinjiang Medical
University from 2007 to 2013. Approximately 3000 patients
undergo coronary angiography every year and we selected
almost 1000 Han CAD patients and 1000 healthy persons
diagnosed by angiography from 2007 to 2013. Highly skilled
physicians were undertaken the coronary angiography
using the Judkins approach. Least two experienced imaging
specialists were interpreted the findings of coronary angiog-
raphy, finally, the diagnosis of CAD was made according to
the angiography report. All CAD groups defined as the
presence of at least one significant coronary artery stenosisof > 50% luminal diameter. Patients with congenital heart
disease, multiple organ failure syndrome, malignancy or
chronic inflammatory disease were excluded. According to
the exclusion criteria, 124 people were excluded from the
1000 CAD patients. Each control subject also underwent a
coronary angiogram and did not show coronary artery sten-
osis. These individuals had no electrocardiographic signs of
CAD, regional wall motion abnormalities, and no relevant
valvular abnormalities in echocardiograms. Control subjects
with CAD and any neoplasm, cardiomyopathy or severe
illness limiting life expectance or refusing consent were ex-
cluded, according to the exclusion criteria, 82 people were
excluded from the 1000 healthy persons. Finally, to ensure
matching for age and gender, we selected 490 patients and
507 healthy persons from the 876 CAD patients and 918
healthy persons. Some of the controls have hypertension,
and diabetes mellitus, which means control group expose
to the same risk factors of CAD while the results of coron-
ary angiogram are normal. The diagnosis of hypertension
was established if patients were on antihypertensive medi-
cation or if the mean of 3 measurements of systolic blood
pressure (SBP) at least 140 mmHg, and/or diastolic blood
pressure (DBP) at least 90 mmHg, or a previous diagnosis
of hypertension and the use of antihypertensive medication;
Diabetes mellitus was defined on the basis of the American
Diabetes Association [22]. In addition, individuals with
fasting plasma glucose > 7.0 mmol/L or with a history
of diabetes or treatment with hypoglycemic agent were
considered diabetic. Smoking was classified as smokers
(including current or ex-smokers) or non-smokers.
Blood collection and DNA extraction
Before cardiac catheterization, 5 ml of fasting venous blood
drawn by venipuncture in the Cardiac Catheterization La-
boratory were taken from all participants. The blood sam-
ples were collected into tubes containing ethylene diamine
tetraacetic acid (EDTA), and centrifuged at 4000 × g for
5 min to separate the plasma content (including plasma,
serum and blood cells). Genomic DNA was extracted
from the peripheral leukocytes using standard phenol-
chloroform method [23]. The DNA samples were stored
at −80°C for future analysis. Before genetic analysis, the
final concentration of the DNA was diluted to 50 ng/μL.
Genotyping
There are 662 SNPs for the human CYP17A1 gene listed
in the National Center for Biotechnology Information
SNP database (http://www.ncbi.nlm.nih.gov/SNP). Using
Haploview 4.2 software and International HapMap Project
website phase I &II database (http://www.hapmap.org),
we obtained five tag SNPs (SNP1: rs4919686, SNP2:
rs1004467, SNP3: rs4919687, SNP4: rs10786712, SNP5:
rs2486758) by using minor allele frequency (MAF) ≥ 0.05
and linkage disequilibrium patterns with r2 ≥ 0.8 as a cut
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was confirmed by the TaqMan SNP Genotyping Assay
(Applied Biosystems, Foster City, CA, USA). The primers
and probes used in the TaqMan SNP Genotyping Assays
were chosen based on information available at the ABI
Web site (http://myscience.appliedbiosystems.com). Ther-
mal cycling was done using the Applied Biosystems 7900HT
Fast Real-Time PCR System. Plates were read on the se-
quence detection systems (SDS) automation controller soft-
ware v2.3 (ABI). PCR amplification was performed using
2.5 μL of TaqMan Universal Master Mix, 0.15 μL probes
and 1.85 ddH2O in a 6-μL final reaction volume containing
1 μL DNA. The thermal cycling conditions were as follows:
50°C for 2 min; 95°C for 10 min; 50 cycles of 95°C for 15 s;
and 60°C for 1 min. Thermal cycling was performed using
the Sequence Detection Systems (SDS) automation control-
ler software v2.3 (ABI).
Biochemical analysis
Serum concentrations of glucose (Glu), total cholesterol
(TC), triglyceride (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C),
blood urea nitrogen (BUN), creatinine (Cr) and uric acid
(UA) were measured using standard methods in the Central
Laboratory of First Affiliated Hospital of Xinjiang Medical
University as described previously [24-26].
Statistical analysis
Data analysis was carried out using the computer software
Statistical Package for Social Sciences SPSS 17.0 for Win-
dows (SPSS Institute, Chicago, USA). Hardy-Weinberg
equilibrium was assessed by χ2 analysis. Differences in
measurement variables (e.g. age, BMI, TC, TG, HDL-C,
LDL-C) were analyzed using means ± standard deviation
(SD). The difference between the CAD and control groups
was analyzed using an independent-sample t-test. Differ-
ences in frequencies of smoking, drinking, hypertension,
diabetes mellitus, and CYP17A1 genotypes were analyzed
using χ2 test or Fisher’s exact test while appropriate.
P-value < 0.05 was considered statistically significant.
Logistic regression analyses with effect ratios (odds ra-
tio [OR] and 95% CI) were used to assess contribution
of major risk factors. Statistical significance was estab-
lished at P < 0.05. Based on the genotype data of the gen-
etic variations, we performed linkage disequilibrium (LD)
analysis and haplotype-based case–control analysis, using
the expectation maximization (EM) algorithm [27] and
the software SHEsis (http://analysis.bio-x.cn/SHEsisMain.
htm). The pairwise linkage disequilibrium analysis was per-
formed using five SNP pairs. We used∣D'∣values of > 0.5 to
assign SNP locations to one haplotype block. Single nucleo-
tide polymorphisms with an r2 value of < 0.5 were selected
as tagged. In the haplotype-based case–control analysis,
haplotypes with a frequency of < 0.03 were excluded. Thefrequency distribution of the haplotypes was calculated by
performing a permutation test using the bootstrap method.Results
Table 1 shows demographic and clinical characteristics of
the study participants. There was no significant difference
in age between CAD patients and control subjects. It
means the study was an age-matched case–control study.
For total subjects, men, and women participants, there was
no significant difference in the following variables between
the CAD patients and the control participants: hyperten-
sion, smoking, drinking, diastolic blood pressure (DBP),
and serum concentration of total cholesterol, low-density
lipoprotein cholesterol, and uric acid. The incidence of dia-
betes, and the plasma concentration of glucose, creatinine
was significantly higher in subjects with CAD than in the
controls. For total participants, the following values were
significantly higher for the CAD patients as compared to
the control subjects: systolic blood pressure (SBP), the
plasma concentration of triglyceride, high-density lipopro-
tein cholesterol. And the plasma concentration of HDL
was significantly lower for patients with CAD than for con-
trol participants. For women, the systolic blood pressure
(SBP), triglyceride, were significantly higher for patients
with CAD than for control participants.
Table 2 shows the distribution of genotypes and alleles
of SNP1, SNP2, SNP3, SNP4 and SNP5 for the CYP17A1
gene. The genotype distributions for each SNP were in
good agreement with the predicted Hardy–Weinberg
equilibrium values (data not shown). For total, men, and
women subjects, the distribution of SNP1 (rs4919686) and
SNP5 (rs2486758) genotypes, dominant model, recessive
model, and additive model did not show a significant dif-
ference between CAD and control participants (P > 0.05,
respectively). For total participants, the other three SNPs
(SNP2: rs1004467, SNP3: rs4919687, SNP4: rs10786712)
genotypes, dominant model, recessive model, additive
model, and allele frequency also did not show a signifi-
cant difference between the CAD patients and the con-
trol subjects (P > 0.05 respectively). For men subjects,
distribution of rs10786712 recessive model (CC +CT vs.
TT) showed difference between CAD and control subjects
(P = 0.016), and the recessive model was significantly
lower in subjects with CAD than in controls (75.7% vs.
66.1%). For women participants, the dominant model
(CC + CT vs. TT) of rs1004467 showed difference between
CAD and control subjects (P = 0.038), and the dominant
model was significantly higher in CAD patients than in
control participants (76.6% vs. 67.8%). The distribution of
the recessive model (AG +GG vs. AA) of rs4919687 was
significantly higher in patients with CAD than in control
participants (89.8% vs. 95.5%), and showed a significant
difference between CAD and control subjects (P = 0.019).
Table 1 Demographic and clinical characteristics of study participants
Total Men Women
CAD Control P value CAD Control P value CAD Control P value
Number(n) 490 507 278 263 212 244
Age, mean (SD) 61.94 (9.97) 61.20 (10.07) 0.242 60.65 (11.11) 59.70 (11.32) 0.326 63.63 (7.95) 62.81 (8.23) 0.280
EH, n (%) 236 (48.2) 219 (43.2) 0.115 119 (42.8) 106 (40.3) 0.555 117 (55.2) 113 (46.3) 0.059
Diabetes, n (%) 102 (20.8) 40 (7.9) <0.001 55 (19.8) 23 (8.7) <0.001 47 (22.2) 17 (7.0) <0.001
Smoking, n (%) 63 (12.9) 50 (9.9) 0.136 60 (21.6) 49 (18.6) 0.392 3 (1.4) 1 (4) 0.519
Drinking, n (%) 55 (11.2) 43 (8.5) 0.146 54 (19.4) 43 (16.3) 0.371 1 (5) 0 0.994
BMI, mean (SD) 25.85 (3.41) 25.48 (3.26) 0.076 26.41 (3.35) 25.72 (3.37) 0.018 25.26 (3.39) 25.16 (3.10) 0.753
SBP, mean (SD) 138.74 (26.35) 135.49 (24.09) 0.045 136.44 (25.77) 134.82 (23.11) 0.448 141.84 (26.87) 136.20 (25.13) 0.024
DBP, mean (SD) 85.78 (18.10) 84.18 (15.66) 0.143 85.48 (18.42) 84.52 (15.94) 0.521 86.17 (17.71) 83.81 (15.38) 0.136
Glu, mean (SD) 6.28 (2.69) 5.55 (1.73) <0.001 6.21 (2.77) 5.62 (1.92) 0.004 6.37 (2.57) 5.48 (1.50) < 0.001
TG, mean (SD) 2.24 (2.13) 1.90 (1.48) 0.005 2.30 (2.10) 2.04 (1.57) 0.110 2.15 (2.17) 1.75 (1.37) 0.026
TC, mean (SD) 4.25 (1.16) 4.33 (1.02) 0.306 4.06 (0.99) 4.18 (1.04) 0.160 4.51 (1.30) 4.48 (0.97) 0.777
HDL, mean (SD) 1.08 (0.33) 1.13 (0.32) 0.013 1.01 (0.28) 1.05 (0.29) 0.148 1.16 (0.38) 1.22 (0.33) 0.104
LDL, mean (SD) 2.51 (0.94) 2.55 (0.86) 0.457 2.43 (0.91) 2.52 (0.89) 0.220 2.80 (2.46) 2.57 (0.82) 0.212
UA, mean (SD) 320.94 (94.17) 321.07 (82.94) 0.982 344.51 (91.79) 348.25 (75.07) 0.609 289.55 (88.13) 291.72 (81.14) 0.788
Cr, mean (SD) 77.79 (33.00) 72.21 (17.82) 0.001 84.09 (33.96) 79.15 (16.84) 0.033 69.39 (29.73) 64.71 (15.71) 0.045
BUN, mean (SD) 5.38 (1.96) 5.29 (1.86) 0.446 5.54 (1.68) 5.51 (1.68) 0.822 5.17 (2.27) 5.05 (2.01) 0.562
Data are presented as mean ± SD or n (%). Continuous variables are expressed as mean ± SD. Categorical variables are expressed as percentages. MI, body mass
index; BUN, blood urea nitrogen; Cr, creatinine; DBP, diastolic blood pressure; DM, diabetes mellitus; Glu, glucose; TG, triglyceride; TC, total cholesterol; HDL, high
density lipoprotein; LDL, low density lipoprotein; EH, essential hypertension; SBP, systolic blood pressure; UA, uric acid.
The P value of the continuous variables was calculated by the Independent t-test. The P value of the categorical variables was calculated by Fisher’s exact test.
Dai et al. Lipids in Health and Disease  (2015) 14:16 Page 4 of 10Tables 3, 4, and 5 showed the multivariable logistic re-
gression analyses done with the following variables:
prevalence of conventional risk factors for CAD includ-
ing hypertension, diabetes, smoking and drinking, and
plasma concentration of blood glucose, TG, Cr, and SBP.
For women (Table 3), after multivariate adjustment,
rs1004467 remains significantly association with CAD in
dominant model (OR = 1.623, 95%CI: 1.023-2.576, P =
0.040); rs4919687 (Table 4) remains significantly associ-
ation with CAD (OR = 0.417, 95%CI: 0.188-0.926, P =
0.032) in recessive model. For men (Table 5), the signifi-
cant difference of rs10786712 (OR = 1.644, 95% confi-
dence interval [CI]:1.087-2.488, P = 0.019) was retained
after adjustment of the major confounding factors for
CAD in recessive model.
Table 6 shows patterns of linkage disequilibrium (LD)
analysis in the CYP17A1. All 5 SNPs are located in one
haplotype block for∣D'∣values were beyond 0.5, and all
of the r2 values were below 0.5. Because the∣D'∣for
SNP2-SNP3 was < 0.5, this meant that SNP2 and SNP3
could not be used to simultaneously construct haplo-
types. As the minor allele frequency of SNP3 was larger
than that of SNP2, we constructed haplotypes using
SNP1, SNP3, SNP4, and SNP5.
Table 7 shows the result of haplotype analysis. In the
haplotype-based case–control analysis, haplotypes were
established through different combinations of the 4SNPs. For total, including men and women, the overall dis-
tribution of haplotypes were no significantly different be-
tween the CAD patients and the control subjects. For men,
the frequencies of the C–T, G–C–T, A–C–T, and A–G–
C–T haplotypes respectively established by SNP4–SNP5,
SNP3–SNP4–SNP5, SNP1–SNP4–SNP5, and SNP1–
SNP3–SNP4–SNP5 were significantly higher for the CAD
patients as compared to the control subjects (P = 0.047, P =
0.048, P = 0.040, and P = 0.039, respectively). The frequen-
cies of the A–A–T, A–T–T, and A–A–T–T haplotypes
respectively established by SNP1–SNP3–SNP5, SNP1–
SNP4–SNP5, and SNP1–SNP3–SNP4–SNP5 were lower
for CAD patients than for control participants (P = 0.040,
P = 0.031, P = 0.033, respectively). For women, the fre-
quency of the A–T, A–A–T, A–A–T, and A–A–T–T hap-
lotypes established by SNP3–SNP4, SNP1–SNP3–SNP4,
SNP1–SNP3–SNP5, and SNP1–SNP3–SNP4–SNP5 re-
spectively were significantly higher for the CAD patients
as compared to the control subjects (P = 0.041, P = 0.034,
P = 0.035, and P = 0.045, respectively).
Discussion
Relationship between CYP genetic polymorphism and
cardiovascular disease (CVD) has been established [10].
In our study, we found the variations in CYP17A1 gene
was associated with CAD in a Han population of China,
even after multivariate adjustment, the association still
Table 2 Genotype and Allele distributions in patients with CAD and control participants
Variants Total Man Woman
CAD, n (%) Control, n (%) P value CAD n (%) Control n (%) P value CAD n (%) Control n (%) P value
Rs4919686 (SNP1)
Genotyping AA 365 (76.2) 356 (77.1) 0.710 205 (75.6) 181 (76.1) 0.836 160 (76.9) 175 (78.1) 0.811
AC 110 (23.0) 100 (21.6) 63 (23.2) 53 (22.3) 47 (22.6) 47 (21.0)
CC 4 (0.8) 6 (1.3) 3 (1.1) 4 (1.7) 1 (0.5) 2 (0.9)
Recessive model CC 4 (0.8) 6 (1.3) 0.707 3 (1.1) 4 (1.7) 0.863 1 (0.5) 2 (0.9) 1
AA + AC 475 (99.2) 456 (98.7) 268 (98.9) 234 (98.3) 207 (99.5) 222 (99.1)
Dominant model AA 365 (76.2) 356 (77.1) 0.756 205 (75.6) 181 (76.1) 0.915 160 (76.9) 175 (78.1) 0.765
AC + CC 114 (23.8) 106 (22.9) 66 (24.4) 57 (23.9) 48 (23.1) 49 (21.9)
Additive model AC 110 (23.0) 100 (21.6) 0.627 63 (23.2) 53 (22.3) 0.793 47 (22.6) 47 (21.0) 0.685
AA + CC 369 (77.0) 362 (78.4) 208 (76.8) 185 (77.7) 161 (77.4) 177 (79.0)
Allele A 840 (87.7) 812 (87.9) 0.897 473 (87.3) 415 (87.2) 0.968 367 (88.2) 397 (88.6) 0.856
C 118 (12.3) 112 (12.1) 69 (12.7) 61 (12.8) 49 (11.8) 51 (11.4)
Rs1004467 (SNP2)
Genotyping CC 86 (17.8) 89 (17.5) 0.993 41 (14.7) 45 (17.1) 0.240 45 (22.0) 44 (18.0) 0.106
CT 250 (51.8) 264 (52.0) 138 (49.6) 142 (54.0) 112 (54.6) 122 (49.8)
TT 147 (30.4) 155 (30.5) 99 (35.6) 76 (28.9) 48 (23.4) 79 (32.2)
Recessive model CC 86 (17.8) 89 (17.5) 0.906 41 (14.7) 45 (17.1) 0.453 45 (22.0) 44 (18.0) 0.290
CT + TT 397 (82.2) 419 (82.5) 237 (85.3) 218 (82.9) 160 (78.0) 201 (82.0)
Dominant model TT 147 (30.4) 155 (30.5) 0.979 99 (35.6) 76 (28.9) 0.095 48 (23.4) 79 (32.2) 0.038
CC + CT 336 (69.6) 353 (69.5) 179 (64.4) 187 (71.1) 157 (76.6) 166 (67.8)
Additive model CT 250 (51.8) 264 (52.0) 0.948 138 (49.6) 142 (54.0) 0.311 112 (54.6) 122 (49.8) 0.306
CC + TT 233 (48.2) 244 (48.0) 140 (50.4) 121 (46.0) 93 (45.4) 123 (50.2)
Allele C 422 (43.7) 442 (43.5) 0.935 220 (39.6) 232 (44.1) 0.130 202 (49.3) 210 (42.9) 0.055
T 544 (56.3) 574 (56.5) 336 (60.4) 294 (55.9) 208 (50.7) 280 (57.1)
Rs4919687 (SNP3)
Genotyping AA 30 (6.3) 24 (4.7) 0.551 9 (3.3) 13 (5.0) 0.538 21 (10.2) 11 (4.5) 0.063
AG 155 (32.4) 171 (33.8) 93 (33.9) 93 (35.5) 62 (30.2) 78 (32.0)
GG 294 (61.4) 311 (61.5) 172 (62.8) 156 (59.5) 122 (59.5) 155 (63.5)
Recessive model AA 30 (6.3) 24 (4.7) 0.295 9 (3.3) 13 (5.0) 0.328 21 (10.2) 11 (4.5) 0.019
AG + GG 449 (93.7) 482 (95.3) 265 (96.7) 249 (95.0) 184 (89.8) 233 (95.5)
Dominant model GG 294 (61.4) 311 (61.5) 0.978 172 (62.8) 156 (59.5) 0.443 122 (59.5) 155 (63.5) 0.384
AA + AG 185(38.6) 195 (38.5) 102 (37.2) 106 (40.5) 83 (40.5) 89 (36.5)
Additive model AG 155 (32.4) 171 (33.8) 0.632 93 (33.9) 93 (35.5) 0.705 62 (30.2) 78 (32.0) 0.695
AA + GG 324 (67.6) 335 (66.2) 181 (66.1) 169 (64.5) 143 (69.8) 166 (68.0)
Allele A 215 (22.4) 219 (21.6) 0.668 111 (20.3) 119 (22.7) 0.328 104 (25.4) 100 (20.5) 0.083
G 743 (77.6) 793 (78.4) 437 (79.7) 405 (77.3) 306 (74.6) 388 (79.5)
Rs10786712 (SNP4)
Genotyping CC 114 (23.7) 96 (20.8) 0.407 64 (23.5) 51 (21.3) 0.055 50 (23.9) 45 (20.2) 0.264
CT 239 (49.7) 228 (49.4) 142 (52.2) 107 (44.8) 97 (46.4) 121 (54.3)
TT 128 (26.6) 138 (29.9) 66 (24.3) 81 (33.9) 62 (29.7) 57 (25.6)
Recessive model TT 128 (26.6) 138 (29.9) 0.266 66 (24.3) 81 (33.9) 0.016 62 (29.7) 57 (25.6) 0.340
CC + CT 353 (73.4) 324 (70.1) 206 (75.7) 158 (66.1) 147 (70.3) 166 (74.4)
Dominant model CC 114 (23.7) 96 (20.8) 0.281 64 (23.5) 51 (21.3) 0.554 50 (23.9) 45 (20.2) 0.348
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Table 2 Genotype and Allele distributions in patients with CAD and control participants (Continued)
CT + TT 367 (76.3) 366 (79.2) 208 (76.5) 188 (78.7) 159 (76.1) 178 (79.8)
Additive model CT 239 (49.7) 228 (49.4) 0.917 142 (52.2) 107 (44.8) 0.093 97 (46.4) 121 (54.3) 0.103
CC + TT 242 (50.3) 234 (50.6) 130 (47.8) 132 (55.2) 112 (53.6) 102 (45.7)
Allele C 467(48.5) 420 (45.5) 0.179 270 (49.6) 209 (43.7) 0.059 197 (47.1) 211 (47.3) 0.958
T 495 (51.5) 504 (54.5) 274 (50.4) 269 (56.3) 221 (52.9) 235 (52.7)
Rs2486758 (SNP5)
Genotyping CC 14 (2.9) 16 (3.2) 0.950 9 (3.3) 10 (3.8) 0.912 5 (2.4) 6 (2.5) 0.983
CT 162 (33.3) 164 (32.8) 95 (34.5) 87 (33.3) 67 (31.6) 77 (32.2)
TT 311 (63.9) 320 (64.0) 171 (62.2) 164 (62.8) 140 (66.0) 156 (65.3)
Recessive model CC 14 (2.9) 16 (3.2) 0.766 9 (3.3) 10 (3.8) 0.727 5 (2.4) 6 (2.5) 0.917
CT + TT 473 (97.1) 484 (96.8) 266 (96.7) 251 (96.2) 207 (97.6) 233 (97.5)
Dominant model TT 311 (63.9) 320 (64.0) 0.964 171 (62.2) 164 (62.8) 0.876 140 (66.0) 156 (65.3) 0.864
CC + CT 176 (36.1) 180 (36.0) 104 (37.8) 97 (37.2) 72 (34.0) 83 (34.7)
Additive model CT 162 (33.3) 164 (32.8) 0.877 95 (34.5) 87 (33.3) 0.767 67 (31.6) 77 (32.2) 0.889
CC + TT 325 (66.7) 336 (67.2) 180 (65.5) 174 (66.7) 145 (68.4) 162 (67.8)
Allele C 190 (19.5) 196 (19.6) 0.959 113 (20.5) 107 (20.1% 0.985 77 (18.2) 89 (18.6) 0.859
T 784 (80.5) 804 (80.4) 437 (79.5) 415 (79.5) 347 (81.8) 389 (81.4)
CAD, Coronary artery disease; N, number of participants; SNP, single-nucleotide polymorphism.
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tween CAD and CYP17A1 gene in Chinese population.
The pathogenesis of CAD includes the disorders of
lipoprotein metabolism [28,29], disturbance of blood co-
agulation and fibrinolytic system [30,31], insulin resist-
ance or diabetes [32,33], hypertension [34,35], and the
impairment and inflammation of vascular endothelium
[36-38]. As previously mentioned, P450c17proteins is an
important enzyme that catalyzes the formation of all en-
dogenous androgens. Therefore, CYP17A1 genetic mu-
tations can loss of the enzyme activity of P450c17 and
potentially reduce androgen biosynthesis.
In recent years, many clinical studies showed that tes-
tosterone levels play an important role in the progress of
CAD among elderly men [39], whereas lower testosteroneTable 3 Multiple logistic regression analysis for CAD patients
Total
OR 95% CI P
Dominant model (CC + CT vs TT) 1.024 0.766- 1.370 0.872
Hypertension 0.988 0.729- 1.340 0.939
Diabetes 2.485 1.619- 3.812 < 0.001
Smoking 1.490 0.827- 2.676 0.184
Drinking, 0.908 0.485- 1.703 0.764
Glucose 1.147 1.058- 1.243 0.001
triglyceride 1.088 1.055- 1.177 0.038
Creatinine 1.099 1.002- 1.005 0.011
SBP 1.003 0.997- 1.009 0.271
CAD, Coronary artery disease; OR, odds ratios; 95%CI, 95% confidence intervals; SBPlevels promote CAD [40]. In addition, some evidences
have indicated that testosterone also was related to the
risk factors of CAD. For example, numerous studies have
confirmed that the dysfunction of vascular endothelial as a
key mechanism of occurrence and development of CAD
[36-38], the levels of physiological testosterone can pro-
mote the endothelial cells release of nitric oxide (NO)
through improve the vascular endothelial function, and
low levels of testosterone can decrease the vascular endo-
thelial function and promote the occurrence of CAD [41].
The disorders of lipoprotein metabolism also one of pri-
mary mechanisms of CAD [28,29], research shows there
was a positive correlation between the levels of testoster-
one and HDL-C, and a negatively correlated between the
levels of testosterone and the TG, TC, LDL-C and VLDL.and control subjects (rs1004467)
Men Woman
OR 95% CI P OR 95% CI P
0.731 0.498- 1.075 0.112 1.623 1.023- 2.576 0.040
0.955 0.635- 1.436 0.825 1.082 0.670- 1.748 0.747
2.246 1.248- 4.044 0.007 2.957 1.556- 5.619 0.001
1.381 0.748- 2.549 0.303 2.291 0.180- 29.077 0.523
0.941 0.493- 1.796 0.845 0 0 1
1.107 0.991- 1.235 0.071 1.198 1.065- 1.347 0.003
1.060 0.960- 1.171 0.249 1.138 0.988- 1.310 0.072
1.009 1.000- 1.018 0.046 1.004 0.991- 1.016 0.567
1.001 0.993- 1.009 0.851 1.006 0.997- 1.015 0.191
, systolic blood pressure.
Table 4 Multiple logistic regression analysis for CAD patients and control subjects (rs4919687)
Total Men Woman
OR 95% CI P OR 95% CI P OR 95% CI P
Recessive model (AG + GG vs AA) 0.673 0.372- 1.217 0.190 1.324 0.512- 3.428 0.563 0.417 0.188- 0.926 0.032
Hypertension 1.001 0.738- 1.358 0.996 0.958 0.637- 1.442 0.838 1.155 0.717- 1.862 0.55
Diabetes 2.484 1.618- 3.814 < 0.001 2.370 1.310- 4.289 0.004 2.857 1.508- 5.411 0.001
Smoking 1.546 0.853- 2.803 0.151 1.455 0.783- 2.701 0.235 2.959 2.33- 37.579 0.403
Drinking, 0.861 0.455- 1.629 0.645 0.864 0.449- 1.662 0.662 0 0 1
Glucose 1.154 1.063- 1.253 0.001 1.094 0.979- 1.223 0.114 1.218 1.080- 1.373 0.001
triglyceride 1.096 1.012- 1.187 0.024 1.064 0.963- 1.175 0.224 1.154 1.003- 1.327 0.045
Creatinine 1.009 1.002- 1.015 0.013 1.009 1.000- 1.018 0.054 1.003 0.991- 1.016 0.606
SBP 1.003 0.997- 1.009 0.272 1.001 0.993- 1.009 0.853 1.005 0.996- 1.014 0.246
CAD, Coronary artery disease; OR, odds ratios; 95%CI, 95% confidence intervals; SBP, systolic blood pressure.
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one can lead to lipid disorders, and supplement testoster-
one can correct dyslipidemia [42]. Insulin resistance and
diabetes are the significant independent risk factors for
CAD [32,33]. Selvin et al. indicated that there is a relation-
ship between diabetes and the low free or low bioactive
testosterone levels [43]. Blood coagulation and fibrinolytic
system is the important mechanism of the CAD [30,31],
physiological levels of testosterone can improve the func-
tion of endothelial cells [44], low levels of testosterone can
increase the proteins related to clotting factor VIII, causing
endothelial dysfunction and vascular inflammatory reac-
tion, finally, platelet adhesion in the damaged blood vessels,
resulting in the incidence of CAD. Androgens serve as pre-
cursors to estrogens, so normal estrogen signaling is also
dependent on CYP17A1. Estrogen plays a very important
role in many other physiological and pathological process,
such as mediation vasoconstriction, vascular endothelium
repair and lipid metabolism, involves in glucose metabol-
ism and insulin related signal transduction pathways, etc.,
which are directly or indirectly affect the function of
cardiovascular system. Wellons et al. reported that earlyTable 5 Multiple logistic regression analysis for CAD patients
Total
OR 95% CI P
Recessive model (CC + CT vs TT) 1.193 0.879- 1.619 0.259
Hypertension 1.010 0.742- 1.377 0.947
Diabetes 2.305 1.481- 3.587 < 0.001
Smoking 1.523 0.833-2.785 0.172
Drinking, 0.825 0.434- 1.567 0.556
Glucose 1.171 1.075- 1.276 < 0.001
triglyceride 1.082 0.999- 1.571 0.052
Creatinine 1.009 1.001- 1.016 0.010
SBP 1.002 0.996- 1.008 0.492
CAD, Coronary artery disease; OR, odds ratios; 95%CI, 95% confidence intervals; SBPmenopause is associated with an increased risk of CAD
[45], as well as high levels of endogenous estrogen explain
the low prevalence of CAD in premenopausal women
[46]. It is worth noting that the protective value of sex
hormones appears to be sex-specific, high levels of estro-
gen and oestrone in men are associated with an increased
risk of and CAD [39].
In our study, we found that polymorphisms of CYP17A1
were associated with risk of CAD in a Han population.
For rs10786712, in men, the recessive model (CC +CT vs
TT) was significantly higher in control subjects than in
CAD patients, after multivariate adjustment of confound-
ing factors such as plasma concentration of TG, Glu, Cr,
incidence of hypertension, diabetes, drinking, and smok-
ing for CAD, the significant difference was retained.
This indicated that the TT genotype might be protecting
against for CAD in men. For rs1004467 and rs4919687, in
women, the dominant model (rs1004467) and recessive
model (rs4919687) were significantly higher in CAD sub-
jects than in control participants, after multivariate adjust-
ment of confounding factors, the significant difference
was retained. This result indicated that CC genotype ofand control subjects (rs10786712)
Men Woman
OR 95% CI P OR 95% CI P
1.644 1.087- 2.488 0.019 0.786 0.495- 1.248 0.308
0.996 0.655- 1.513 0.985 1.117 0.691- 1.805 0.651
2.458 1.313- 4.600 0.005 2.433 1.278- 4.630 0.007
1.421 0.756- 2.669 0.275 2.637 0.210- 33.171 0.453
0.835 0.431- 1.618 0.593 0 0 1
1.111 0.988- 1.250 0.079 1.227 1.084- 1.388 0.001
1.062 0.960- 1.175 0.243 1.134 0.986- 1.304 0.077
1.010 1.000-1.019 0.046 1.005 0.993- 1.017 0.433
0.999 0.990- 1.007 0.795 1.005 0.996- 1.014 0.281
, systolic blood pressure.
Table 6 Pairwise linkage disequilibrium for five SNPs
∣D'∣ values
r2 values SNP1 SNP2 SNP3 SNP4 SNP5
SNP1 0.575 0.911 1.000 0.913
SNP2 0.035 0.470 0.567 0.630
SNP3 0.407 0.049 0.874 0.723
SNP4 0.123 0.219 0.194 0.926
SNP5 0.028 0.074 0.036 0.236
∣D'∣ above the diagonal and r2 below the diagonal.
Table 7 Haplotype analysis in patients with CAD and in contr
Haplotype No. 1 No. 2 No. 3 No. 4 Overall P value Freque
Total Man Woman CAD
SNP3 SNP5 0.877 0.340 0.105
H1 A T 0.217
H2 G C 0.183
H3 G T 0.591
SNP4 SNP5 0.399 0.099 0.964
H1 C C 0.192
H2 C T 0.294
H3 T T 0.509
SNP1 SNP3 SNP4 0.612 0.167 0.155
H1 A A T 0.094
H2 A G C 0.471
H3 A G T 0.299
SNP1 SNP3 SNP5 0.961 0.225 0.154
H1 A A T 0.098
H2 A G C 0.186
H3 C A T 0.116
SNP1 SNP4 SNP5 0.415 0.117 0.986
H1 A C T 0.295
H2 A T T 0.385
H3 C T T 0.122
SNP3 SNP4 SNP5 0.463 0.211 0.282
H1 A T T 0.211
H2 G C C 0.180
H3 G C T 0.291
SNP1 SNP3 SNP4 SNP5 0.577 0.098 0.302
H1 A A T T 0.092
H2 A G C C 0.181
H3 A G C T 0.292
H4 A G T T 0.294
H5 C A T T 0.117
CAD, Coronary artery disease; haplotype with frequencies >0.03 were estimated usi
bootstrap method; SNP, single-nucleotide polymorphism.
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for CAD in women.
In addition, we hypothesized that haplotype analysis
would be useful for the assessment of association be-
tween haplotypes and CAD. For men, we found a sus-
ceptible haplotype [A-C-T (SNP1-SNP4-SNP5)], and a
protective haplotype [A-T-T (SNP1-SNP4-SNP5)]. And
these haplotypic analysis results were consistent with
the genotypic analysis results of SNP4 (rs10786712) that
the CC genotype confers risk and the TT genotype is pro-
tective. For women, significant differences were found
for the frequency of occurrence of the haplotype (A-T
of SNP3-SNP5, A-A-T of SNP1-SNP3-SNP4, A-A-T ofol subjects
ncy in total Frequency in man Frequency in woman
Control P value CAD Control P value CAD Control P value
0.206 0.617 0.188 0.222 0.190 0.249 0.189 0.041
0.182 0.985 0.188 0.196 0.754 0.170 0.167 0.951
0.597 0.686 0.609 0.570 0.182 0.573 0.627 0.074
0.186 0.793 0.201 0.195 0.857 0.180 0.177 0.985
0.268 0.235 0.299 0.241 0.047 0.288 0.296 0.787
0.535 0.201 0.494 0.550 0.055 0.528 0.520 0.854
0.094 0.981 0.070 0.104 0.053 0.127 0.082 0.034
0.446 0.280 0.487 0.436 0.102 0.449 0.456 0.834
0.327 0.192 0.307 0.324 0.552 0.290 0.331 0.189
0.096 0.933 0.067 0.103 0.040 0.135 0.088 0.035
0.181 0.795 0.192 0.194 0.972 0.173 0.167 0.853
0.109 0.701 0.119 0.117 0.893 0.110 0.102 0.742
0.268 0.225 0.302 0.242 0.040 0.286 0.296 0.733
0.419 0.104 0.364 0.427 0.031 0.415 0.411 0.953
0.115 0.668 0.127 0.121 0.830 0.114 0.109 0.830
0.205 0.776 0.190 0.221 0.219 0.239 0.187 0.071
0.177 0.905 0.190 0.189 0.968 0.165 0.164 0.976
0.266 0.239 0.297 0.241 0.048 0.284 0.292 0.761
0.094 0.878 0.066 0.103 0.033 0.127 0.084 0.045
0.177 0.851 0.191 0.189 0.949 0.169 0.165 0.913
0.226 0.221 0.300 0.243 0.039 0.280 0.290 0.693
0.326 0.124 0.297 0.324 0.360 0.291 0.329 0.213
0.110 0.673 0.121 0.116 0.817 0.110 0.103 0.753
ng SHEsis software; P value was calculated by permutation test using the
Dai et al. Lipids in Health and Disease  (2015) 14:16 Page 9 of 10SNP1-SNP3-SNP5, and A-A-T-T of SNP1-SNP3-SNP4-
SNP5, respectively).
There are still several limitations must be mentioned
in the present study. Firstly, we did not perform enzym-
atic LDL, which would decrease the mean and SD of
the LDL results. Secondly, we did not collect the data
on lipid-lowering drug levels and drug compliance. Finally,
this study was limited by the relatively small sample size, it
needs a large number of clinical samples and investigation
of other SNPs of CYP17A1 in future studies.
Conclusion
In conclusion, this is the first study to investigate the dif-
ferences between the human CYP17A1 and CAD in Han
population of China, and is the first haplotype-based
case–control study and to correlations its association with
CAD. Rs1004467, rs4919687, rs10786712 of CYP17A1-
gene are associated with CAD in Han population of China.
The TT genotype of rs10786712 could be a protective
genetic marker of CAD in men. The CC genotype of
rs1004467 and the AA genotype of rs4919687 could be
two risk genetic marker of CAD in women. However, large
sample size study including other SNPs of CYP17A1
should be performed in future studies.
Competing interests
The authors declared that they have no competing interests.
Authors’ contributions
XX and CFD conceived the study, participated in the design, collected the
data, performed statistical analyses, performed the genotyping, and drafted
the manuscript. ZYF, YYZ, YTM, YNY and XML conceived the study and
revised manuscript. FL, BDC and MTG participated in the design, and helped
to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by National Natural Science Foundation of China
(81160017 and 81470014) and Xinjiang Science and Technology Projects
(201491181).
Received: 4 October 2014 Accepted: 29 January 2015
References
1. Manace LC, Godiwala TN, Babyatsky MW. Genomics of cardiovascular
disease. Mt Sinai J Med. 2009;76:613–23.
2. Zee RY1, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of
arachidonate 5-lipoxygenase-acti-vating protein, and risk of incident
myocardial infarction and ischemic stroke: a nested case–control approach.
Stroke. 2006;37:2007–11.
3. Maouche S, Schunkert H. Strategies beyond genome-wide association
studies for atherosclerosis. Arterioscler Thromb Vasc. 2012;32:170–81.
4. Roberts R, Stewart AF. Genes and coronary artery disease: where are we?
J Am Coll Cardiol. 2012;60:1715–21.
5. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk
for 301 ischemic heart disease. J Mol Cell Cardiol. 2005;39:667–79.
6. Damani SB, Topol EJ. Emerging genomic applications in coronary artery
disease. J ACC Cardiovasc. 2011;4:473–82.
7. O'Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwang SJ. Genome-wide
association study for coronary artery calcification with follow-Up in
myocardial infarction. J Circulation. 2012;124:2855–64.
8. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H. Large-scale
association analysis identifies 13 new susceptibility loci for coronary artery
disease. J Nat Genet. 2011;43:333–8.9. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on
arachidonic acid metabolism and their impact on cardiovascular diseases.
Pharmacol Ther. 2010;125:446–63.
10. Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in
cardiovascular health and disease. Pharmacol Ther. 2006;112:564–87.
11. Nakayama T, Soma M, Rehemudula D, Takahashi Y, Tobe H, Satoh M.
Association of 5’ upstream promoter region of prostacyclin synthase gene
variant with cerebral infarction. Am J Hypertens. 2000;13:1263–7.
12. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1
MspI polymorphism on cigarette smoking related coronary artery disease
and diabetes. Atherosclerosis. 2002;162:391–7.
13. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2
increases the risk of myocardial infarction. J Med Genet. 2004;41:758–62.
14. Yasar U1, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, et al.
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial
infarction. Pharmacogenetics. 2003;13:715–20.
15. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk
of coronary artery disease associated with polymorphism of the cytochrome
P450 epoxygenase CYP2J2. Circulation. 2004;110:2132–6.
16. Hengstenberg C1, Holmer SR, Mayer B, Löwel H, Engel S, Hense HW, et al.
Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in
patients with myocardial infarction. Hypertension. 2000;35:704–9.
17. Letonja M, Peterlin B, Bregar D, Petrovic D. Are the T/C polymorphism of
the CYP17 gene and the tetranucleotide repeat (TTTA) polymorphism of the
CYP19 gene genetic markers for premature coronary artery disease in
Caucasians? Folia Biol (Praha). 2005;51:76–81.
18. Fan YM1, Raitakari OT, Kähönen M, Hutri-Kähönen N, Juonala M, Marniemi J,
et al. Hepatic lipase promoter C-480 T polymorphism is associated with
serum lipids levels, but not subclinical atherosclerosis: the Cardiovascular
Risk in Young Finns Study. Clin Genet. 2009;76:46–53.
19. Nehal N, Mehta MD. MSCE: Large-Scale Association Analysis Identifies 13
New Susceptibility Loci for Coronary Artery Disease. Circ Cardiovasc Genet.
2011;4:327–9.
20. Schunkert H1, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al.
Large-scale association analyses identifies 13 new susceptibility loci for
coronary artery disease. Nat Genet. 2011;43:333–8.
21. Butterworth AS, Braund PS, Farrall M. Large-scale gene-centric analysis identifies
novel variants for coronary artery disease. PLoS Genet. 2011;7:e1002260.
22. American Diabetes Association. Clinical practice recommendations. Diabetes
Care. 1997;20:S1–S70.
23. Nakayama T, Soma M, Rahmutula D, Ozawa Y, Kanmatsuse K. Isolation of
the 5-flanking region of genes by thermal asymmetric interlaced polymerase
chain reaction. Med Sci Monit. 2001;7:345–9.
24. Xiang X, Ma YT, Fu ZY, Yang YN, Xiang M, Chen BD, et al. Haplotype
Analysis of the CYP8A1 gene associated with myocardial infarction.
Clin Appl Thromb-Hem. 2009;15:574–80.
25. Xie X, Ma YT, Fu ZY, Yang YN, Ma X, Chen BD, et al. Association of
polymorphisms of PTGS2 and CYP8A1 with myocardial infarction.
Clin Chem Lab Med. 2009;47:347–52.
26. Yang YN, Wang XL, Ma YT, Xie X, Fu ZY, Li XM, et al. Association of interaction
between smoking and CYP 2C19*3 polymorphism with coronary artery disease
in a Uighur population. Clin Appl Thromb Hemost. 2010;16:579–83.
27. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from in complete
data via the EM algorithm. J R Stat Soc. 1977;39:1–22.
28. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Kastelein JJ, Khaw KT,
et al. The hypertriglyceridemic-waist phenotype and the risk of coronary
artery disease: results from the EPIC-Norfolk prospective population study.
CMAJ. 2010;182:1427–32.
29. Goswami B1, Rajappa M, Singh B, Ray PC, Kumar S, Mallika V. Inflammation
and dyslipidaemia: a possible interplay between established risk factors
in North Indian males with coronary artery disease. Cardiovasc J Afr.
2010;21:103–8.
30. Maruyama I. Coagulation/fibrinolytic system and platelet in acute coronary
syndrome. Nihon Rinsho. 1998;56:2488–92.
31. Folsom AR1, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective
study of fibrinolytic factors and incident coronary heart disease: the
Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc
Biol. 2001;21:611–7.
32. Raz I. Relationship between blood glucose control and improved
cardiovascular outcome after stent implantation in diabetic patients.
Cardiology. 2010;116:48–50.
Dai et al. Lipids in Health and Disease  (2015) 14:16 Page 10 of 1033. Reaven GM. Insulin resistance, the insulin resistance syndrome, and
cardiovascular disease. Panmineva Med. 2005;47:201–10.
34. Srikanthan VS, Dunn FG. Hypertension and coronary artery disease.
Med Clin North Am. 1997;81:1147–63.
35. Nakamura Y, Saitoh S, Takagi S, Ohnishi H, Chiba Y, Kato N, et al. Impact of
abnormal glucose tolerance, hypertension and other risk factors on
coronary artery disease. Circ J. 2007;71:20–5.
36. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inflammation
and traditional risk factors in atherosclerosis and coronary artery disease.
J Am Coll Cardiol. 1998;31:1217–25.
37. Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler
Rep. 2002;4:92–8.
38. Kitta Y, Obata JE, Nakamura T, Hirano M, Kodama Y, Fujioka D, et al.
Persistent impairment of endothelial vasomotor function has a negative
impact on outcome in patients with coronary artery disease. J Am Coll
Cardiol. 2009;53:323–30.
39. Naessen T1, Sjogren U, Bergquist J, Larsson M, Lind L, Kushnir MM.
Endogenous steroids measured by high-specificity liquid chromatography-
tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old
men and women. J Clin Endocrinol Metab. 2010;95:1889–97.
40. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum
testosterone and increased mortality in men with coronary heart disease.
Heart. 2010;96:1821–5.
41. Maturana MA1, Breda V, Lhullier F, Spritzer PM. Relationship between
endogenous testosterone and cardiovascular risk in early postmenopausal
women. Metabolism. 2008;57:961–5.
42. Malkin CJ1, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect
of testosterone replacement on endogenous inflammatory eytokines and
lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–8.
43. Selvin E, Feinleib M, Zhang L. Androgens and diabetes in men results from
the Third National Health and Nutrition Examination Survey (NHANES III).
Diabetes Care. 2007;30:234–8.
44. Jin H, Lin J, Fu L. Physiological testosterone stimulates tissue plasminogen
activator and tissue factor pathway inhibitor and inhibits plasminogen
activator inhibitor type l release in endothelial cells. Biochem Cell Bid.
2007;85:246–51.
45. Wellons M, Ouyang P, Schreiner PJ. Early menopause predicts future
coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis.
Menopause. 2012;19:1081–7.
46. Mendelsohn ME, Karas RH. The protective effects of estrogen on the
cardiovascular system. N EngI J Med. 1999;340:1801–11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
